Yekyung Kong
Physical Medicine & Rehabilitation · West Orange, NJNPI 1134117419
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,327 of the $60,850 with a category attached, or 74.5%. 28 manufacturers reported payments, led by Johnson & Johnson at 42.2% of the total. Reporting peaked in 2019 at $27,496 and has fallen 98.9% since, to $307 in 2025. Among physical medicine & rehabilitation clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $325.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$26K
- Merz Pharmaceuticals, LLC$21K
- Merz North America, Inc.$13K
- Ipsen Pharma SAS$593
- AbbVie$282
- Abbott$145
- plus $700 from 22 others
What the payments were for
- Consulting fees$5,6639%
- Speaking & faculty fees$45,32774%
- Travel & lodging$6,07610%
- Food & beverage$3,7846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 44 | $25,679 |
| Merz Pharmaceuticals, LLC | 51 | $20,714 |
| Merz North America, Inc. | 24 | $12,737 |
| Ipsen Pharma SAS | 3 | $593 |
| AbbVie(2 entities) | 18 | $282 |
| Abbott | 2 | $145 |
| Coloplast | 5 | $101 |
| Azurity Pharmaceuticals, Inc. | 6 | $98 |
| Argenx US, Inc. | 4 | $70 |
| Daiichi Sankyo Inc. | 4 | $59 |
| Pfizer | 3 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $41 |
| Vertex | 2 | $29 |
| Bioventus LLC | 1 | $29 |
| Collegium Pharmaceutical, Inc. | 2 | $27 |
| AstraZeneca | 2 | $27 |
| Pacira Therapeutics, Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Biogen | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
| Virtus Pharmaceuticals LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,850 in reported general payments places this provider in the 95th percentile of 434 physical medicine & rehabilitation providers in New Jersey.
See all physical medicine & rehabilitation providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $40,459 |
| OxycontinOxycodone Hcl | 20 | $36,849 |
| RoxicodoneOxycodone Hcl | 22 | $33,095 |
| LinzessLinaclotide | 40 | $24,288 |
| XareltoRivaroxaban | 16 | $13,726 |
| EliquisApixaban | 22 | $12,279 |
| MovantikNaloxegol Oxalate | 27 | $10,947 |
| Lubiprostone | 39 | $5,028 |
| Gabapentin | 203 | $2,106 |
| Diclofenac Sodium | 73 | $1,652 |
| Baclofen | 137 | $1,453 |
| Oxycodone Hcl | 88 | $1,401 |
| Morphine Sulfate ErMorphine Sulfate | 31 | $713 |
| Tramadol Hcl | 57 | $643 |
| Escitalopram Oxalate | 81 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $41 | $40,45925 claims |
| AbbVieLinzess | $282 | $24,28840 claims |
| Johnson & JohnsonXarelto | $25,679 | $13,72616 claims |
| PfizerEliquis | $45 | $12,27922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 physical medicine & rehabilitation providers in New Jersey.
Other physical medicine & rehabilitation in West Orange
- Steven KirshblumWest Orange$47K
- Steven EscaldiEdison$70K
- Joseph IbrahimBayonne$50K
- Joseph ValenzaChester$29K
- Christine GreissEdison$28K
- Bianca MartinezManasquan$25K
- Jason SmithCedar Knolls$19K
- Sandeep RathiLakewood$14K
- Anand PooleriCamden$13K
- Cristin McKennaEast Hanover$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.